Form 990 for tax year 2024
Filed by GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC.
Totals
- Total revenue
- $63,732,557
- Total expenses
- $61,508,783
- Contributions and grants received
- $52,737,212
- Grants paid
- $359,938
- Program service revenue
- $0
- Investment income
- $9,675,203
- Other revenue
- $1,320,142
- Total assets, end of year
- $204,316,428
- Total liabilities, end of year
- $28,006,599
- Net assets or fund balances, end of year
- $176,309,829
- Program services expenses (Part IX)
- $54,417,744
- Management and general expenses
- $5,733,341
- Fundraising expenses
- $1,357,698
- Program service expenses (Part III)
- $54,417,744
Program services were 88.5% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.
Line items
Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.
Revenue
Part VIII, the statement of revenue.
-
1e · Government grants (contributions)
$35,728,256
-
1f · All other contributions, gifts and grants
$17,008,956
-
2f · All other program service revenue
total $0 · related or exempt $0 · unrelated business $0 · excluded $0
-
3 · Investment income
total $6,018,797 · related or exempt $0 · unrelated business $0 · excluded $6,018,797
-
5 · Royalties
total $387,789 · related or exempt $0 · unrelated business $0 · excluded $387,789
-
6c · Rental income or loss
real property $0 · personal property $0
-
7a · Gross sales of assets other than inventory
securities $142,380,115
-
7b · Less cost or other basis and sales expenses
securities $138,723,709
-
7c · Gain or loss
securities $3,656,406 · other assets $0
-
7d · Net gain or loss
total $3,656,406 · related or exempt $0 · unrelated business $0 · excluded $3,656,406
-
8c · Net income from fundraising events
total $0
-
11a · Other revenue: MISCELLANEOUS INCOME
total $932,353 · related or exempt $0 · unrelated business $0 · excluded $932,353
-
11d · All other revenue
total $0 · related or exempt $0 · unrelated business $0 · excluded $0
-
11e · Other revenue, total
$932,353
Functional expenses
Part IX, the statement of functional expenses.
-
3 · Grants to foreign organizations and individuals
total $359,938 · program services $359,938
-
4 · Benefits paid to or for members
total $0 · program services $0
-
5 · Compensation of officers, directors and key employees
total $4,529,643 · program services $3,106,359 · management and general $1,077,293 · fundraising $345,991
-
7 · Other salaries and wages
total $10,141,255 · program services $7,961,031 · management and general $1,635,853 · fundraising $544,371
-
8 · Pension plan contributions
total $942,313 · program services $744,950 · management and general $146,067 · fundraising $51,296
-
9 · Other employee benefits
total $1,606,557 · program services $1,260,908 · management and general $264,453 · fundraising $81,196
-
10 · Payroll taxes
total $742,235 · program services $564,161 · management and general $134,862 · fundraising $43,212
-
11b · Fees: legal
total $822,060 · program services $722,908 · management and general $99,152 · fundraising $0
-
11c · Fees: accounting
total $142,596 · program services $43,000 · management and general $99,596 · fundraising $0
-
11f · Fees: investment management
total $281,815 · program services $0 · management and general $281,815 · fundraising $0
-
11g · Fees: other
total $5,644,699 · program services $5,161,190 · management and general $407,709 · fundraising $75,800
-
13 · Office expenses
total $202,203 · program services $17,307 · management and general $183,058 · fundraising $1,838
-
14 · Information technology
total $1,082,116 · program services $439,587 · management and general $605,447 · fundraising $37,082
-
16 · Occupancy
total $1,178,518 · program services $858,816 · management and general $242,283 · fundraising $77,419
-
17 · Travel
total $904,955 · program services $607,018 · management and general $237,153 · fundraising $60,784
-
19 · Conferences, conventions and meetings
total $105,276 · program services $92,770 · management and general $12,506 · fundraising $0
-
22 · Depreciation, depletion and amortization
total $263,420 · program services $193,961 · management and general $51,513 · fundraising $17,946
-
23 · Insurance
total $215,254 · program services $60,704 · management and general $154,550 · fundraising $0
-
24a · Other expenses: R&D PROJECT EXPENSES
total $32,128,355 · program services $32,128,355 · fundraising $0
-
24b · Other expenses: DUES AND SUBSCRIPTIONS
total $215,575 · program services $94,781 · management and general $100,031 · fundraising $20,763
-
24e · All other expenses
total $0 · program services $0 · management and general $0 · fundraising $0
Balance sheet
Part X, book values.
-
1 · Cash, non-interest-bearing
beginning of year $5,606,240 · end of year $0
-
2 · Savings and temporary cash investments
beginning of year $138,316,993 · end of year $34,377,400
-
3 · Pledges and grants receivable
beginning of year $1,821,719 · end of year $6,609,856
-
4 · Accounts receivable
beginning of year $1,102,554 · end of year $1,081,288
-
5 · Loans and receivables from officers and key people
beginning of year $0 · end of year $0
-
6 · Loans and receivables from disqualified persons
beginning of year $0 · end of year $0
-
9 · Prepaid expenses and deferred charges
beginning of year $1,426,170 · end of year $1,196,922
-
10a · Land, buildings and equipment: cost or other basis
$6,538,126
-
10b · Land, buildings and equipment: accumulated depreciation
$5,217,651
-
10c · Land, buildings and equipment, net
beginning of year $1,535,911 · end of year $1,320,475
-
11 · Investments: publicly traded securities
beginning of year $31,709,868 · end of year $80,443,114
-
12 · Investments: other securities
beginning of year $0 · end of year $64,373,689
-
13 · Investments: program-related
beginning of year $0
-
15 · Other assets
beginning of year $15,800,086 · end of year $14,913,684
-
17 · Accounts payable and accrued expenses
beginning of year $8,012,001 · end of year $8,739,913
-
19 · Deferred revenue
beginning of year $1,205,080 · end of year $2,621,045
-
22 · Loans and payables to officers and key people
beginning of year $0 · end of year $0
-
25 · Other liabilities
beginning of year $16,402,910 · end of year $16,645,641
-
27 · Net assets without donor restrictions
beginning of year $171,699,550 · end of year $176,309,829
Mission and programs · 2024
Mission
TB ALLIANCE IS A NOT-FOR-PROFIT ORGANIZATION DEDICATED TO THE DISCOVERY, DEVELOPMENT AND DELIVERY OF BETTER, FASTER-ACTING AND AFFORDABLE TUBERCULOSIS DRUGS THAT ARE AVAILABLE TO THOSE WHO NEED THEM.
Activities or mission (Part I)
TO ACCELERATE THE DISCOVERY & DEVELOPMENT OF NEW DRUGS TO FACILITATE THE CONTROL OF TUBERCULOSIS THROUGHOUT THE WORLD AND THE ACCESSIBILITY OF THESE DRUGS TO THE GLOBAL COMMUNITY.
-
RESEARCH AND DEVELOPMENT - TB ALLIANCE IS A NOT-FOR-PROFIT PRODUCT DEVELOPMENT PARTNERSHIP (PDP), UNIQUELY POSITIONED TO LEVERAGE A GLOBAL NETWORK OF PUBLIC AND PRIVATE PARTNERS TO MOST EFFICIENTLY ADVANCE TB DRUG DEVELOPMENT. A PDP BUILDS PARTNERSHIPS BETWEEN THE PUBLIC, PRIVATE, ACADEMIC, AND PHILANTHROPIC SECTORS TO DRIVE THE DEVELOPMENT OF NEW PRODUCTS FOR UNDERSERVED MARKETS. PDPS RETAIN DIRECT MANAGEMENT OVERSIGHT OF THEIR PROJECTS, THOUGH MUCH OF THE LABORATORY AND CLINICAL WORK IS DONE THROUGH EXTERNAL RESEARCH FACILITIES AND CONTRACTORS. WE COMBINE THE RESEARCH AND DEVELOPMENT EXPERTISE OF OUR STAFF WITH THE SKILLS AND RESOURCES OF OUR PARTNERS TO HARNESS THE MOST PROMISING SCIENCE WHEREVER IT MAY EXIST AROUND THE WORLD. THIS MODEL MINIMIZES COSTS, INCLUDING OVERHEAD AND INVESTMENTS IN INFRASTRUCTURE, WHILE OPTIMIZING SCIENTIFIC CAPABILITY TO SPEED NEW TB DRUG DEVELOPMENT. OUR BUSINESS MODEL AND DIVERSE PARTNERSHIPS ALLOW TB ALLIANCE TO LEVERAGE ADDITIONAL PARTNER SERVICES FOR EVERY DOLLAR INVESTED IN ITS PROGRAMS. NC-009 - NC-009 IS A PAN-PHASE 2 CLINICAL TRIAL INCORPORATING ELEMENTS OF PHASE 2A, B, AND C TO EVALUATE THE SAFETY AND EFFICACY OF A COMBINATION OF A NEW EXPERIMENTAL COMPOUND, TBAJ-876, WITH PRETOMANID AND LINEZOLID, COMPONENTS OF TB ALLIANCE'S BPAL REGIMEN. THIS REGIMEN HAS THE POTENTIAL TO SHORTEN AND IMPROVE TREATMENT FOR BOTH DRUG-SENSITIVE AND DRUG-RESISTANT FORMS OF TB. RESULTS FROM PRECLINICAL AND PHASE 1 STUDIES WERE PRESENTED AT THE 2023 UNION CONFERENCE ON LUNG HEALTH AND SHOWED THAT THE NEW COMPOUND, TBAJ-876, WHEN COMPARED WITH BEDAQUILINE (A TB MEDICINE IN THE SAME DRUG CLASS), ELIMINATED TB BACTERIA FASTER AND HAD A POTENTIALLY SAFER PROFILE. NC-009 WILL TEST DIFFERENT DOSES OF TBAJ-876 IN COMBINATION WITH PRETOMANID AND LINEZOLID AGAINST THE CURRENT STANDARD OF CARE FOR DRUG-SENSITIVE TB - ISONIAZID, RIFAMPICIN, PYRAZINAMIDE, AND ETHEMBUTOL (HRZE). ANOTHER ARM OF THE TRIAL WILL ALSO TEST PRETOMANID AND LINEZOLID IN COMBINATION WITH BEDAQUILINE (BPAL), A REGIMEN NOW RECOMMENDED BY THE WORLD HEALTH ORGANIZATION TO TREAT SOME FORMS OF DR-TB, AGAINST DRUG-SENSISTIVE TB. THE STUDY ENROLLED APPRXIMATELY 300 PARTICIPANTS WITH DRUG-SENSITIVE TB AT 21 CLINICAL TRIAL SITES IN FIVE COUNTRIES: GEORGIA, PHILIPPINES, SOUTH AFRICA, TANZANIA, AND UGANDA. Q203 - TELACEBEC (Q203) IS A FIRST-IN-CLASS DRUG CANDIDATE AGAINST MYCOBACTERIUM TUBERCULOSIS INFECTION. Q203 TARGETS CYTOCHROME BC1 COMPLEX AND SHOWS POTENT ACTIVITY AGAINST MULTIDRUG-RESISTANT TUBERCULOSIS (MDR-TB). Q203 HAS ALSO BEEN FOUND EFFECTIVE AGAINST BURULI ULCER (MYCOBACTERIUM ULCERANS), A CHRONIC, NECROTIZING DISEASE THAT AFFECTS SKIN AND SOMETIMES BONE AND CAN LEAD TO PERMANENT DEFORMITY AND LONG-TERM DISABILITY, AND LEPROSY (MYCOBACTERIUM LEPRAE). IN 2023, TB ALLIANCE IN-LICENSED Q203 FROM QURIENT, A CLINICAL-STAGE BIOTECHNOLOGY COMPANY BASED IN SOUTH KOREA. IN JULY 2024, A PHASE 2 PROOF-OF-CONCEPT STUDY WAS INITIATED TO EXPLORE THE USE OF TELACEBEC (Q203) TO TREAT BURULI ULCER. IF SUCCESSFUL, A SINGLE DRUG COULD CUT TREATMENT DURATION BY MORE THAN HALF. IN PARTNERSHIP WITH TB ALLIANCE AND WITH SUPPORT FROM QURIENT CO. LTD, PROFESSOR DANIEL O'BRIEN - A PROMINENT CLINICIAN-RESEARCHER AND EXPERT IN BURULI ULCER - IS LEADING THE STUDY AT BARWON HEALTH AND THE ROYAL MELBOURNE HOSPITAL IN AUSTRALIA. THE TRIAL WILL ENROLL APPROXIMATELY 40 ADULT PATIENTS WITH BURULI ULCER WHO WILL RECEIVE 28 DAYS OF TELACEBEC (300MG) ONCE DAILY, FOLLOWED BY A YEAR OF OBSERVATION. PRELIMINARY RESULTS ARE EXPECTED IN 2025. TBAJ-587 - THIS NEXT-GENERATION DIARYLQUINOLINE PROJECT HAS SHOWN POTENTIAL TO MAINTAIN BEDAQUILINE'S IMPRESSIVE ANTI-TB ACTIVITIES WHILE RETAINING ADDITIONAL IMPROVED PROPERTIES. TBAJ-587 IS BEING STUDIED THROUGH THE INNOVATIVE HEALTH INITIATIVE'S ERA4TB PROJECT AND, IN 2024, TBAJ-587 COMPLETED A PHASE I TRIAL DEMONSTRATING POSITIVE RESULTS. RESULTS PUBLICATIONS ARE UNDERWAY. SUTEZOLID - SUTEZOLID IS A PROMISING CLINICAL-STAGE TB DRUG CANDIDATE FROM THE OXAZOLIDINONE CLASS. TB ALLIANCE HAS IMPLEMENTED AN OPEN DEVELOPMENT APPROACH TO ADVANCE THE PHASE 2 TB DRUG CANDIDATE, SUTEZOLID, WHICH COULD BE A COMPONENT OF A NEXT-GENERATION TB REGIMEN. TB ALLIANCE HAS MADE SUTEZOLID AVAILABLE FOR STUDY BY ALL RESEARCHERS WHO COMMIT TO MAKING THEIR RESULTS AVAILABLE TO THE BROADER TB RESEARCH COMMUNITY. THIS NOVEL APPROACH HAS CONTRIBUTED TO THREE CLINICAL TRIALS THAT BEGAN IN 2023. PEERLINC - IN 2024, TB ALLIANCE LAUNCHED A NEW PEER-TO-PEER LEARNING FOR INNOVATIVE CURES (PEERLINC) KNOWLEDGE HUB BASED IN MANILA, WITH FUNDING FROM THE AUSTRALIAN GOVERNMENT THROUGH THE PARTNERSHIPS FOR A HEALTHY REGION INITIATIVE. PEERLINC, OPERATING IN PARTNERSHIP BETWEEN TB ALLIANCE AND THE TROPICAL DISEASE FOUNDATION, INC. (TDF), AND IN CLOSE COLLABORATION WITH THE DEPARTMENT OF HEALTH (DOH), PHILIPPINES, WILL HELP COUNTRIES IMPLEMENT BEST PRACTICES IN THE TREATMENT OF DRUG-RESISTANT TUBERCULOSIS (DR-TB) TO HELP SPEED THE WORLDWIDE PROGRAMMATIC IMPLEMENTATION OF INNOVATIVE, MORE EFFECTIVE TREATMENTS FOR THE DISEASE, STARTING WITH THE WORLD HEALTH ORGANIZATION (WHO)-RECOMMENDED SIX-MONTH, ALL-ORAL BPAL/M REGIMENS, COMPOSED OF THE ANTIBIOTICS BEDAQUILINE (B), PRETOMANID (PA), AND LINEZOLID (L), WITH OR WITHOUT MOXIFLOXACIN (M). PEERLINC WILL PROVIDE PRACTICAL TRAINING AND TECHNICAL ASSISTANCE TO COUNTRIES TO SUPPORT THIS OBJECTIVE, VIA EXPERTS FROM THE PHILIPPINES AND THE DEPARTMENT OF HEALTH, INCLUDING LUNG CENTER OF THE PHILIPPINES AND THE NATIONAL TB REFERENCE LABORATORY (NTRL). THE PHILIPPINES HAS SUCCESSFULLY AND RAPIDLY DEPLOYED NEW TREATMENTS THROUGH PARTICIPATION IN TB ALLIANCE'S LEVERAGING INNOVATION FOR FASTER TB TREATMENT (LIFT-TB) INITIATIVE. IN 2024 ALONE, THE PEERLINC KNOWLEDGE HUB COMPLETED TRAININGS WITH LEADERS, EXPERTS, AND STAFF FROM NATIONAL TB PROGRAMS IN SEVEN COUNTRIES: PERU, DRC, NIGERIA, BRAZIL, CAMBODIA, TANZANIA, RWANDA. LIFT-TB (LEVERAGING INNOVATION FOR FASTER TREATMENT OF TB) - THIS ACCESS PROGRAM, LAUNCHED IN 2020, SEEKS TO INCREASE TREATMENT COMPLETION RATES FOR DRUG-RESISTANT TB THROUGH ADOPTION AND SCALE UP OF NEW REGIMENS, BEGINNING WITH BPAL. IT FOCUSES ON SEVEN HIGH-BURDEN SOUTHEAST AND CENTRAL ASIAN COUNTRIES THAT SHOULDER APPROXIMATELY 1 IN 5 OF THE GLOBAL TB CASES. AS OF 2024, MORE THAN 100 COUNTRIES HAVE PROCURED THE SIX-MONTH, ALL-ORAL BPAL REGIMEN TO TREAT MORE THAN 180,000 PEOPLE WITH DRUG-RESISTANT TB. FAST TRACK THE CURE - IN SUPPORT OF THE WORLD HEALTH ORGANIZATION'S CALL TO ACTION TO ACCELERATE ACCESS TO SHORTER DR-TB CURES FOR ALL, THE FAST TRACK THE CURE MOVEMENT BRINGS COMMUNITIES AROUND THE WORLD TOGETHER TO RAISE AWARENESS AND FACILITATE ACCESS TO NEW DR-TB TREATMENTS, WHILE RAMPING UP ADVOCACY TO CONVINCE WORLD LEADERS THAT SIX-MONTH DR-TB CURES MUST BE WIDELY ADOPTED AND AVAILABLE TO ALL WHO NEED THEM. FAST TRACK THE CURE IS ALSO COLLABORATING CLOSELY WITH STOP TB TO ENSURE STRATEGIC ALIGNMENT AND PARTNERSHIP AND WITH THE CHALLENGE FACILITY FOR CIVIL SOCIETY MOVEMENT, BY ALIGNING WITH THEIR COMMUNITY ENGAGEMENT, CAPACITY BUILDING, AND DEMAND CREATION PILLARS AND FOCUS. SLASH-TB - TB ALLIANCE AND THE SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE HAVE DEVELOPED SLASH-TB (SAVINGS FROM LEVERAGING & ADOPTING SHORTER & HIGHLY EGGECTIVE TB TREATMENTS), A MODEL TO ESTIMATE COST SAVINGS FOR HEALTH SERVICE SYSTEMS, PATIENTS, FAMILIES, AND/OR CAREGIVERS WHEN USING THE BPAL/M REGIMENS AS COMPARED TO STANDARD DRUG-RESISTANT TB TREATMENTS.
Expenses $47,923,018
-
PUBLIC AFFAIRS AND POLICY - TB ALLIANCE MAINTAINS CRITICAL ALLIANCES WITH PUBLIC AND PRIVATE ORGANIZATIONS TO RAISE AWARENESS ABOUT TUBERCULOSIS ("TB") AND ADVOCATE FOR PUBLIC AND PRIVATE INVOLVEMENT IN RESEARCH FOR THE PUBLIC GOOD. SPECIFICALLY, TB ALLIANCE NEGOTIATES TERMS THAT SUPPORT THE DEVELOPMENT AND ACCESS OF NEW AFFORDABLE ANTI-TB DRUGS EQUITABLY FOR THOSE AREAS MOST IN NEED WHILE ENCOURAGING THE PRIVATE SECTOR ON THE DEVELOPMENT OF THESE MEDICINES. TB ALLIANCE CONTINUES TO PURSUE AN EXPLICIT COMMITMENT TO OUR "AAA MANDATE" - THAT ALL NEW PRODUCTS WILL BE ADOPTED, AVAILABLE AND AFFORDABLE TO THOSE WITH TB.
Expenses $5,642,489 · Grants $359,938
-
BUSINESS DEVELOPMENT - TB ALLIANCE NEGOTIATES, IMPLEMENTS AND MANAGES AGREEMENTS WITH PUBLIC AND PRIVATE ORGANIZATIONS WORLDWIDE AND DOES SO BY ADHERING TO SOUND BUSINESS PRACTICES WHILE ENSURING THE PUBLIC GOOD. SPECIFICALLY, TB ALLIANCE NEGOTIATES TERMS THAT SUPPORT THE DEVELOPMENT AND ACCESS OF NEW AFFORDABLE ANTI-TB DRUGS EQUITABLY TO THOSE AREAS MOST IN NEED WHILE ENCOURAGING THE PRIVATE SECTOR TO HELP DEVELOP NEW MEDICINES FOR TB INDICATIONS.
Expenses $852,237
As filed on the 2024 return.
Listed in Part VII
-
Ariel Pablos-MendezARIEL PABLOS-MENDEZ
VICE-CHAIR
- Total calculated
- $0
- Hours/week
- 3
-
David NortonDAVID NORTON
CHAIR
- Total calculated
- $0
- Hours/week
- 3
-
Dr Melvin SpigelmanDR MELVIN SPIGELMAN
PRESIDENT/CEO
- Total calculated
- $1,052,936
- From this org
- $939,703
- From related orgs
- $0
- Other
- $113,233
- Hours/week
- 45
Schedule J breakdown matched by us
- Base
- $664,638
- Bonus
- $275,065
- Other
- $0
- Deferred
- $69,000
- Nontaxable benefits
- $44,233
- Filer's total
- $1,052,936
-
Akshay VaishnawAKSHAY VAISHNAW
DIRECTOR (AS OF 12/01/24)
- Total calculated
- $0
- Hours/week
- 3
-
Ann TaylorANN TAYLOR
DIRECTOR (AS OF 09/01/24)
- Total calculated
- $0
- Hours/week
- 3
-
Eric GoosbyERIC GOOSBY
DIRECTOR
- Total calculated
- $0
- Hours/week
- 3
-
Kim SchwartzKIM SCHWARTZ
DIRECTOR
- Total calculated
- $0
- Hours/week
- 3
-
Mitchell WarrenMITCHELL WARREN
DIRECTOR
- Total calculated
- $0
- Hours/week
- 3
-
Rasha HibriRASHA HIBRI
DIRECTOR
- Total calculated
- $0
- Hours/week
- 3
-
Ratan WatalRATAN WATAL
DIRECTOR
- Total calculated
- $0
- Hours/week
- 3
-
Srishti GuptaSRISHTI GUPTA
DIRECTOR (AS OF 12/01/24)
- Total calculated
- $0
- Hours/week
- 3
-
Sundar KodiyalamSUNDAR KODIYALAM
DIRECTOR
- Total calculated
- $0
- Hours/week
- 3
-
Angela VanderploegANGELA VANDERPLOEG
TREASURER/CFO
- Total calculated
- $526,225
- From this org
- $421,854
- From related orgs
- $0
- Other
- $104,371
- Hours/week
- 45
Schedule J breakdown matched by us
- Base
- $334,028
- Bonus
- $87,826
- Other
- $0
- Deferred
- $42,395
- Nontaxable benefits
- $61,976
- Filer's total
- $526,225
-
Colleen PeroCOLLEEN PERO
SECRETARY/CAO
- Total calculated
- $541,142
- From this org
- $470,044
- From related orgs
- $0
- Other
- $71,098
- Hours/week
- 45
Schedule J breakdown matched by us
- Base
- $375,473
- Bonus
- $94,571
- Other
- $0
- Deferred
- $46,106
- Nontaxable benefits
- $24,992
- Filer's total
- $541,142
-
Dr Eugene SunDR EUGENE SUN
SR. VP, RESEARCH & DEVELOPMENT
- Total calculated
- $674,243
- From this org
- $580,925
- From related orgs
- $0
- Other
- $93,318
- Hours/week
- 45
Schedule J breakdown matched by us
- Base
- $461,947
- Bonus
- $118,978
- Other
- $0
- Deferred
- $54,642
- Nontaxable benefits
- $38,676
- Filer's total
- $674,243
-
Dr Nader FotouhiDR NADER FOTOUHI
SR. VP, CHIEF SCIENTIFIC OFFICER
- Total calculated
- $683,612
- From this org
- $565,207
- From related orgs
- $0
- Other
- $118,405
- Hours/week
- 45
Schedule J breakdown matched by us
- Base
- $448,750
- Bonus
- $116,457
- Other
- $0
- Deferred
- $56,266
- Nontaxable benefits
- $62,139
- Filer's total
- $683,612
-
Maria BeumontMARIA BEUMONT
VP, CHIEF MEDICAL OFFICER
- Total calculated
- $584,002
- From this org
- $497,709
- From related orgs
- $0
- Other
- $86,293
- Hours/week
- 45
Schedule J breakdown matched by us
- Base
- $412,534
- Bonus
- $85,175
- Other
- $0
- Deferred
- $46,000
- Nontaxable benefits
- $40,293
- Filer's total
- $584,002
-
Pietro O TurilliPIETRO O TURILLI
SR. VP, EXTERNAL AFFAIRS
- Total calculated
- $467,483
- From this org
- $369,474
- From related orgs
- $0
- Other
- $98,009
- Hours/week
- 45
Schedule J breakdown matched by us
- Base
- $293,361
- Bonus
- $76,113
- Other
- $0
- Deferred
- $36,741
- Nontaxable benefits
- $61,268
- Filer's total
- $467,483
-
Kathleen SchostackKATHLEEN SCHOSTACK
SR. VP, PROGRAM & ALLIANCE MANAGEMENT
- Total calculated
- $518,559
- From this org
- $432,300
- From related orgs
- $0
- Other
- $86,259
- Hours/week
- 45
Schedule J breakdown matched by us
- Base
- $343,593
- Bonus
- $88,707
- Other
- $0
- Deferred
- $42,820
- Nontaxable benefits
- $43,439
- Filer's total
- $518,559
-
Rajneesh TanejaRAJNEESH TANEJA
VP, PHARMACEUTICAL PRODUCT DEVELOPMENT
- Total calculated
- $451,668
- From this org
- $370,728
- From related orgs
- $0
- Other
- $80,940
- Hours/week
- 45
Schedule J breakdown matched by us
- Base
- $306,440
- Bonus
- $64,288
- Other
- $0
- Deferred
- $36,902
- Nontaxable benefits
- $44,038
- Filer's total
- $451,668
-
Robert LoretteROBERT LORETTE
SR. VP, BUSINESS DEVELOPMENT
- Total calculated
- $536,240
- From this org
- $448,954
- From related orgs
- $0
- Other
- $87,286
- Hours/week
- 45
Schedule J breakdown matched by us
- Base
- $357,997
- Bonus
- $90,957
- Other
- $0
- Deferred
- $43,907
- Nontaxable benefits
- $43,379
- Filer's total
- $536,240
-
Salah ForaidaSALAH FORAIDA
SR. DIRECTOR, MEDICAL AFFAIRS
- Total calculated
- $482,498
- From this org
- $430,090
- From related orgs
- $0
- Other
- $52,408
- Hours/week
- 45
Schedule J breakdown matched by us
- Base
- $373,254
- Bonus
- $56,836
- Other
- $0
- Deferred
- $42,937
- Nontaxable benefits
- $9,471
- Filer's total
- $482,498
-
Sandeep JunejaSANDEEP JUNEJA
SR. VP, MARKET ACCESS
- Total calculated
- $521,229
- From this org
- $417,509
- From related orgs
- $0
- Other
- $103,720
- Hours/week
- 45
Schedule J breakdown matched by us
- Base
- $330,811
- Bonus
- $86,698
- Other
- $0
- Deferred
- $41,851
- Nontaxable benefits
- $61,869
- Filer's total
- $521,229
Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.
Schedule J
Answered yes
- 3 · Compensation committee
- 3 · Independent compensation consultant
- 3 · Form 990 of other organizations
- 3 · Compensation survey or study
- 3 · Approval by the board or compensation committee
- 7 · Other non-fixed payments
Answered no
- 4a · Severance or change-of-control payment
- 4b · Supplemental nonqualified retirement plan
- 4c · Equity-based compensation arrangement
- 5a · Pay contingent on this organization's revenues
- 5b · Pay contingent on a related organization's revenues
- 6a · Pay contingent on this organization's net earnings
- 6b · Pay contingent on a related organization's net earnings
- 8 · Paid under the initial-contract exception
The filer's explanations (Part III)
- Schedule J, Part I, Line 7 Non-fixed payments
- VARIABLE COMPENSATION IS PAID TO STAFF MEMBERS BASED ON ANNUAL PERFORMANCE. REFER TO SCHEUDLE O RESPONSE TO FORM 990, PART VI, SECTION B, LINES 15 A and 15B FOR FURTHER DETAILS.
Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.
Grants on this return
No itemized grants to organizations on this return.
Provenance
- Return type
- form_990
- Tax year
- 2024
- Filed
- 24 October 2025
- IRS schema version
- 2024v5.1
- Source object
- 202542969349302084
Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.
The source document this was parsed from is served over the API, which is where bulk and document access live.